{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:51:37Z","timestamp":1788184297983,"version":"build-2803163510"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chronic pain remains to be a clinical challenge and is recognized as a major health problem with varying impacts on quality of life. Currently, the first-line therapy for chronic pain is opioids, which are often accompanied by unwanted psychoactive side effects. Thus, new and effective treatments for chronic pain are urgently needed and eagerly pursued. Inflammatory cytokines, especially interleukin-17 (IL-17), are reportedly potential therapeutic targets owing to their pivotal role in chronic pain from the neuroinflammation perspective. Recently, substantial evidence confirmed that IL-17 and IL-17 receptors (IL-17Rs) were increased in neuropathic, inflammatory, and cancer pain models. Notably, IL-17\/IL-17R antibodies also reportedly relieve or cure inflammatory- and pain-related diseases. However, existing studies have reported controversial results regarding IL-17\/IL-17Rs as potential therapeutic targets in diverse animal models of chronic pain. In this review, we present a summary of published studies and discuss the evidence, from basic to clinical to research, regarding the role and mechanism of action between IL-17 and diverse kinds of chronic pain in animal models and clinical patients. Furthermore, we evaluated IL-17-based therapy as a potential therapeutic strategy for inflammatory- and pain-related disease. Importantly, we also discussed clinical trials of IL-17\/IL-17R targeting monoclonal antibodies. Overall, we found that IL-17 is a potential therapeutic target for chronic pain from the perspective of neuroinflammation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.999407","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T01:02:37Z","timestamp":1664413357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":52,"title":["Interleukin-17 as a potential therapeutic target for chronic pain"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaojuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/j.pain.0000000000001384","article-title":"Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the international classification of diseases (ICD-11)","volume":"160","author":"Treede","year":"2019","journal-title":"Pain"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1109084","article-title":"Alleviating suffering 101\u2013pain relief in the united states","volume":"366","author":"Pizzo","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2004.07.009","article-title":"Imaging of acute versus pathological pain in humans","volume":"9","author":"Lorenz","year":"2005","journal-title":"Eur J Pain"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-018-0012-5","article-title":"Transition to chronic pain: opportunities for novel therapeutics","volume":"19","author":"Price","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4334","article-title":"Emerging targets in neuroinflammation-driven chronic pain","volume":"13","author":"Ji","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and central sensitization in chronic and widespread pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-018-2579-4","article-title":"Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain","volume":"33","author":"Matsuda","year":"2019","journal-title":"J Anesth"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9369-6","article-title":"The IL-17 family cytokines in immunity and disease","volume":"30","author":"Pappu","year":"2010","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.857164","article-title":"The role of IL-17-Mediated inflammatory processes in the pathogenesis of intervertebral disc degeneration and herniation: A comprehensive review","volume":"10","author":"Suyama","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1749-6632.2010.05825.x","article-title":"The IL-17 pathway as a major therapeutic target in autoimmune diseases","volume":"1217","author":"Hu","year":"2011","journal-title":"Ann NY Acad Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1402-7","article-title":"The role of IL-17 in CNS diseases","volume":"129","author":"Waisman","year":"2015","journal-title":"Acta Neuropathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23571","article-title":"Neuroinflammation in the central nervous system: Symphony of glial cells","volume":"67","author":"Yang","year":"2019","journal-title":"Glia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10334","DOI":"10.1038\/s41598-017-10509-5","article-title":"Interleukin-17A is involved in mechanical hyperalgesia but not in the severity of murine antigen-induced arthritis","volume":"7","author":"Ebbinghaus","year":"2017","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":":2384-97.e5","DOI":"10.1016\/j.celrep.2019.10.085","article-title":"Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy","volume":"29","author":"Luo","year":"2019","journal-title":"Cell Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2014.03.004","article-title":"Lomax AE. participation of interleukin 17A in neuroimmune interactions","volume":"41","author":"Moynes","year":"2014","journal-title":"Brain Behav Immun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.11.066","article-title":"Roles of inflammation response in microglia cell through toll-like receptors 2\/interleukin-23\/interleukin-17 pathway in cerebral ischemia\/reperfusion injury","volume":"176","author":"Lv","year":"2011","journal-title":"Neuroscience"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2172-14-20","article-title":"Inhibitory effect of IL-17 on neural stem cell proliferation and neural cell differentiation","volume":"14","author":"Li","year":"2013","journal-title":"BMC Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-019-0411-9","article-title":"Translating neural stem cells to neurons in the mammalian brain","volume":"26","author":"Zahr","year":"2019","journal-title":"Cell Death Differ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-6-14","article-title":"Functional interleukin-17 receptor a is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis","volume":"6","author":"Das Sarma","year":"2009","journal-title":"J Neuroinflamm"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057307","article-title":"CNS-targeted production of IL-17A induces glial activation, microvascular pathology and enhances the neuroinflammatory response to systemic endotoxemia","volume":"8","author":"Zimmermann","year":"2013","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jneuroim.2007.11.006","article-title":"Production and functions of IL-17 in microglia","volume":"194","author":"Kawanokuchi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03009","article-title":"Cytokines in pain: Harnessing endogenous anti-inflammatory signaling for improved pain management","volume":"10","author":"Vanderwall","year":"2019","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.03.035","article-title":"IL-17 induces hyperalgesia via TNF-dependent neutrophil infiltration","volume":"152","author":"McNamee","year":"2011","journal-title":"Pain"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2234","article-title":"Interactions between the immune and nervous systems in pain","volume":"16","author":"Ren","year":"2010","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pain.2012.10.022","article-title":"Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model","volume":"154","author":"Meng","year":"2013","journal-title":"Pain"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70143-5","article-title":"Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment","volume":"9","author":"Baron","year":"2010","journal-title":"Lancet Neurol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-7537-3_9","article-title":"Advances in the treatment of neuropathic pain","volume":"904","author":"Xu","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/1744806918798408","article-title":"The etiological changes of acetylation in peripheral nerve injury-induced neuropathic hypersensitivity","volume":"14","author":"Wang","year":"2018","journal-title":"Mol Pain"},{"key":"B33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1152\/physrev.00045.2019","article-title":"Neuropathic pain: From mechanisms to treatment","volume":"101","author":"Finnerup","year":"2021","journal-title":"Physiol Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neulet.2011.01.079","article-title":"Interleukin-17 levels in rat models of nerve damage and neuropathic pain","volume":"493","author":"Noma","year":"2011","journal-title":"Neurosci Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.03.014","article-title":"T Cell infiltration after chronic constriction injury of mouse sciatic nerve is associated with interleukin-17 expression","volume":"200","author":"Kleinschnitz","year":"2006","journal-title":"Exp Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.08.003","article-title":"Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice","volume":"12","author":"Kim","year":"2011","journal-title":"J Pain"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.04.004","article-title":"Lack of interleukin-17 leads to a modulated micro-environment and amelioration of mechanical hypersensitivity after peripheral nerve injury in mice","volume":"155","author":"Day","year":"2014","journal-title":"Pain"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2012.11.006","article-title":"Neuronal IL-17 receptor upregulates TRPV4 but not TRPV1 receptors in DRG neurons and mediates mechanical but not thermal hyperalgesia","volume":"52","author":"Segond von Banchet","year":"2013","journal-title":"Mol Cell Neurosci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.11.006","article-title":"IL-17 mediates articular hypernociception in antigen-induced arthritis in mice","volume":"148","author":"Pinto","year":"2010","journal-title":"Pain"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31827d4b82","article-title":"Nerve injury-related autoimmunity activation leads to chronic inflammation and chronic neuropathic pain","volume":"118","author":"Li","year":"2013","journal-title":"Anesthesiology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/mmr.2016.6018","article-title":"IL-17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of proinflammatory cytokines","volume":"15","author":"Sun","year":"2017","journal-title":"Mol Med Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-015-9322-z","article-title":"Interleukin-17A acts to maintain neuropathic pain through activation of CaMKII\/CREB signaling in spinal neurons","volume":"53","author":"Yao","year":"2016","journal-title":"Mol Neurobiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-119","article-title":"Immunodominant fragments of myelin basic protein initiate T cell-dependent pain","volume":"9","author":"Liu","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12974-015-0377-6","article-title":"The alternatively spliced fibronectin CS1 isoform regulates IL-17A levels and mechanical allodynia after peripheral nerve injury","volume":"12","author":"Liu","year":"2015","journal-title":"J Neuroinflamm"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0633-4","article-title":"Neuropathic pain after spinal cord injury: Challenges and research perspectives","volume":"15","author":"Shiao","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/786947","article-title":"The role of IL-17 promotes spinal cord neuroinflammation via activation of the transcription factor STAT3 after spinal cord injury in the rat","volume":"2014","author":"Zong","year":"2014","journal-title":"Mediators Inflammation"},{"key":"B47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12974-016-0630-7","article-title":"C-c motif chemokine ligand 20 regulates neuroinflammation following spinal cord injury via Th17 cell recruitment","volume":"13","author":"Hu","year":"2016","journal-title":"J Neuroinflamm"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/srep41779","article-title":"IL-17 induces reactive astrocytes and up-regulation of vascular endothelial growth factor (VEGF) through JAK\/STAT signaling","volume":"7","author":"You","year":"2017","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: A comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.006","article-title":"Inflammation 2010: new adventures of an old flame","volume":"140","author":"Medzhitov","year":"2010","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":":1-164","DOI":"10.1016\/s0301-0082(98)00048-3","article-title":"The induction of pain: an integrative review","volume":"57","author":"Millan","year":"1999","journal-title":"Prog Neurobiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.brainresrev.2008.12.020","article-title":"Role of interleukin-1beta during pain and inflammation","volume":"60","author":"Ren","year":"2009","journal-title":"Brain Res Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/art.37695","article-title":"Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents","volume":"64","author":"Richter","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.4448","article-title":"The mediation of interleukin-17 and chemokine ligand 2 in pelvic pain of experimental autoimmune prostatitis","volume":"14","author":"Liu","year":"2017","journal-title":"Exp Ther Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2008.02.003","article-title":"Role of cytokines in mediating mechanical hypernociception in a model of delayed-type hypersensitivity in mice","volume":"12","author":"Cunha","year":"2008","journal-title":"Eur J Pain"},{"key":"B57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12967-016-0833-9","article-title":"IL-17 mediates inflammatory reactions via p38\/c-fos and JNK\/c-jun activation in an AP-1-dependent manner in human nucleus pulposus cells","volume":"14","author":"Li","year":"2016","journal-title":"J Transl Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis-head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6797","article-title":"Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1","volume":"151","author":"Sommer","year":"1998","journal-title":"Exp Neurol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.neulet.2006.01.018","article-title":"Spinal NMDA receptor phosphorylation correlates with the presence of neuropathic signs following peripheral nerve injury in the rat","volume":"399","author":"Ultenius","year":"2006","journal-title":"Neurosci Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"Ruiz de Morales","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":":jem.20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S227175","article-title":"Applying serum cytokine levels to predict pain severity in cancer patients","volume":"13","author":"Fazzari","year":"2020","journal-title":"J Pain Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2019.01.024","article-title":"Imbalanced spinal infiltration of Th17\/Treg cells contributes to bone cancer pain via promoting microglial activation","volume":"79","author":"Huo","year":"2019","journal-title":"Brain Behav Immun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23928","article-title":"Neuroprotectin\/protectin D1 protects against neuropathic pain in mice after nerve trauma","volume":"74","author":"Xu","year":"2013","journal-title":"Ann Neurol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010611-134636","article-title":"Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control","volume":"52","author":"Zeilhofer","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B69","doi-asserted-by":"publisher","first-page":":169.e1-12","DOI":"10.1016\/j.ejpain.2010.06.003","article-title":"Phosphorylation of spinal n-methyl-d-aspartate receptor NR1 subunits by extracellular signal-regulated kinase in dorsal horn neurons and microglia contributes to diabetes-induced painful neuropathy","volume":"15","author":"Daulhac","year":"2011","journal-title":"Eur J Pain"},{"key":"B70","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3390\/md10020281","article-title":"Tetrodotoxin (TTX) as a therapeutic agent for pain","volume":"10","author":"Nieto","year":"2012","journal-title":"Mar Drugs"},{"key":"B71","doi-asserted-by":"publisher","first-page":":989-1003","DOI":"10.1016\/j.bbadis.2007.01.008","article-title":"TRP channels: targets for the relief of pain","volume":"1772","author":"Levine","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-7-27","article-title":"Hypotonicity modulates tetrodotoxin-sensitive sodium current in trigeminal ganglion neurons","volume":"7","author":"Li","year":"2011","journal-title":"Mol Pain"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.11.009","article-title":"Microglia in pain: Detrimental and protective roles in pathogenesis and resolution of pain","volume":"100","author":"Chen","year":"2018","journal-title":"Neuron"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0218-1","article-title":"Astrocytes in chronic pain and itch","volume":"20","author":"Ji","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.conb.2019.11.006","article-title":"Regulation of pain by neuro-immune interactions between macrophages and nociceptor sensory neurons","volume":"62","author":"Chen","year":"2020","journal-title":"Curr Opin Neurobiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":":1096-103","DOI":"10.1213\/01.ANE.0000055362.56604.78","article-title":"The role of interleukin-6 in nociception and pain","volume":"96","author":"De Jongh","year":"2003","journal-title":"Anesth Analg"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20170907.004","article-title":"[Effect of proinflammatory factors TNF-\u03b1,IL-1\u03b2, IL-6 on neuropathic pain]","volume":"42","author":"Li","year":"2017","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3402-08.2008","article-title":"Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain","volume":"28","author":"Racz","year":"2008","journal-title":"J Neurosci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2017.06.001","article-title":"CXCL1\/CXCR2 signaling in pathological pain: Role in peripheral and central sensitization","volume":"105","author":"Silva","year":"2017","journal-title":"Neurobiol Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2008.02.072","article-title":"Does COX2-dependent PGE2 play a role in neuropathic pain","volume":"437","author":"Ma","year":"2008","journal-title":"Neurosci Lett"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2021.04.002","article-title":"Local and systemic expression pattern of MMP-2 and MMP-9 in complex regional pain syndrome","volume":"22","author":"Escolano-Lozano","year":"2021","journal-title":"J Pain"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-13-05437.2003","article-title":"Phosphorylation of CREB and mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections","volume":"23","author":"Hoeger-Bement","year":"2003","journal-title":"J Neurosci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8861994","article-title":"Electroacupuncture attenuates CFA-induced inflammatory pain by regulating CaMKII","volume":"2020","author":"Gu","year":"2020","journal-title":"Neural Plast"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.injury.2013.04.010","article-title":"Th17 lymphocyte levels are higher in patients with ruptured than non-ruptured lumbar discs, and are correlated with pain intensity","volume":"44","author":"Cheng","year":"2013","journal-title":"Injury"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.04.099","article-title":"Cytokine expression in patients with bladder pain syndrome\/interstitial cystitis ESSIC type 3C","volume":"192","author":"Logadottir","year":"2014","journal-title":"J Urol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2018.0031","article-title":"Th17 and IL-17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain","volume":"69","author":"Zou","year":"2018","journal-title":"Endokrynol Pol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/npr2.12010","article-title":"Association between rs2275913 single-nucleotide polymorphism of the interleukin-17A gene and perioperative analgesic use in cosmetic orthognathic surgery","volume":"38","author":"Ohka","year":"2018","journal-title":"Neuropsychopharmacol Rep"},{"key":"B88","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1042\/CS20110496","article-title":"IL-17\/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential","volume":"122","author":"Zhu","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"R164","DOI":"10.1186\/ar4347","article-title":"A phase ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis","volume":"15","author":"Martin","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0001-7310(14)70015-8","article-title":"IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease","author":"Mitra","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0143-7","article-title":"Secukinumab: a review in moderate to severe plaque psoriasis","volume":"16","author":"Garnock-Jones","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: A review in ankylosing spondylitis","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0579-y","article-title":"Ixekizumab: First global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1410133","article-title":"Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis","volume":"18","author":"Toussirot","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1559730","article-title":"Ixekizumab for the treatment of psoriasis: an update on new data since first approval","volume":"15","author":"Blegvad","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B99","article-title":"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline c-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study","volume":"37","author":"Deodhar","year":"2019","journal-title":"Clin Exp Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.999407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T01:02:44Z","timestamp":1664413364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.999407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2022.999407"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.999407","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"article-number":"999407"}}